Wider-than-Expected Loss at Dynavax - Analyst Blog

By
A A A

Dynavax Technologies Corporation ( DVAX ) suffered a loss of 11 cents per share in the first quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 10 cents per share but flat year over year.

Dynavax reported revenues of $2.1 million, down 11.3% from a year ago but marginally beating the Zacks Consensus Estimate of $2 million.

Collaboration revenues came in at $0.8 million, down 5.0% from the year-ago quarter. Grant revenue from Dynavax's contract for adjuvant development awarded by the National Institutes of Health declined 30.1% to $0.8 million from the prior year.

Research and development expenses came in at $14.2 million in the first quarter of 2013, up 14.2% driven primarily by the purchase of components for candidate Heplisav along with increase in severance expenses.

General and administrative expenses came in at $8.8 million, a significant jump of 52% from the first quarter of 2012. Incremental severance expenses contributed to the increase.

Dynavax is developing Heplisav, in collaboration with GlaxoSmithKline ( GSK ). We note that Heplisav is currently under review in the US and Europe.

In Feb 2013, Dynavax received a setback in its efforts to get the candidate approved in the US. The US Food and Drug Administration (FDA) issued a Complete Response Letter to the company refusing to approve Heplisav in patients in the age group 18-70 without further evaluation of safety.

Dynavax intends to meet the FDA in Jun 2013 to discuss the steps necessary to get the candidate approved. Apart from Heplisav, Dynavax is also developing AZD1419, for the treatment of asthma, in partnership with AstraZeneca ( AZN ).

Dynavax carries a Zacks Rank #3 (Hold). Right now, Anika Therapeutics Inc . ( ANIK ) looks well placed with a Zacks Rank #1 (Strong Buy).



ANIKA THERAPEUT (ANIK): Free Stock Analysis Report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

DYNAVAX TECH CP (DVAX): Free Stock Analysis Report

GLAXOSMITHKLINE (GSK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ANIK , AZN , DVAX , GSK

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Cheap Ways to Sleep Better
Cheap Ways to Sleep Better          

Stocks

Referenced

Most Active by Volume

105,679,298
  • $16.13 ▼ 0.19%
43,130,824
  • $101.32 ▲ 0.74%
24,108,376
  • $59.80 ▲ 7.34%
22,524,427
  • $26.15 ▼ 1.06%
22,194,114
  • $24.65 ▼ 0.96%
21,835,360
  • $99.05 ▲ 0.15%
20,872,575
  • $34.94 ▼ 0.60%
20,561,803
    $74.57 unch
As of 8/22/2014, 04:02 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com